Advertisement
To access the live webcast, please log on to the Company's website atwww.cvt.com and go to the Investor Information section. Alternatively,domestic callers may participate in the conference call by dialing(866) 524-6241, and international callers may participate in the conferencecall by dialing (706) 679-3061. Webcast and telephone replays of theconference call will be available approximately two hours after the completionof the call through Friday, May 2, 2008. Domestic callers can access thereplay by dialing (800) 642-1687, and international callers can access thereplay by dialing (706) 645-9291; the PIN access number is 43615588.
Advertisement
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is abiopharmaceutical company primarily focused on applying molecular cardiologyto the discovery, development and commercialization of novel, small moleculedrugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved products include Ranexa(R) (ranolazineextended- release tablets), indicated for the treatment of chronic angina inpatients who have not achieved an adequate response with other antianginaldrugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologicstress agent in radionuclide myocardial perfusion imaging studies in patientsunable to undergo adequate exercise stress. CV Therapeutics also has otherclinical and preclinical drug development candidates and programs.
SOURCE CV Therapeutics, Inc.
